|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial显示文摘 | Baptist Gallwitz Julio Rosenstock Thomas Rauch Sudipta Bhattacharya Sanjay Patel Maximilian von Eynatten Klaus A Dugi Hans-Juergen Woerle | 2012 | The Lancet2012，，9840： | 2 |
| 2 | Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects显示文摘 | MEIER J J GALLWITZ B KASK B | 2004 | Diabetes2004，53，3： | 1 |
| 3 | Glucagon-like peptide-1 analogues for Type 2 dia- betes mellitus: current and emerging agents显示文摘 | GALLWITZ B | 2011 | Drags2011，71，13： | 1 |
| 4 | Normalization of glucoseconcentrations and deceleration of gastric emptying after solidmeals during intravenous glucagon-like peptide 1in patients withtype 2diabetes显示文摘 | Meier J J Gallwitz B Salmen S | 2003 | J Clin Endocrinol Metab2003，88，6： | 1 |
| 5 | The evolving place of incretin-based therapies in type 2 diabetes显示文摘 | Baptist Gallwitz | 2010 | Pediatric Nephrology2010，，7： | 1 |
| 6 | Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1显示文摘 | Siegel EG Seidenstucker Gallwitz B | 2000 | J Endocrinology2000，164，： | 1 |
| 7 | Normalization of glucose con- centrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes 显示文摘 | Meier J J Gallwitz B Salmen S | 2003 | J Clin Endocrinol Metab2003，88，： | 1 |
| 8 | Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with mefformin failure (EUREXA): an open-la- bel, randomised controlled triM显示文摘 | GALLWITZ B GUZMAN J DOTrA F | 2012 | Lancet2012，379，9833： | 1 |
| 9 | Evidence for an intron-contained sequence required for the splicing of yeast RNA polymerase II transcripts显示文摘 | Lanford C J Gallwitz D | | 0，，： | 1 |
| 10 | Saxagliptin is non-in- ferior to glipizide in patients with type 2 diabetes mellitus in- adequately controlled on metformin alone : a 52-week random- ised controlled trial显示文摘 | Gake B Gallwitz B Eriksson J | 2010 | Int J Clin Pract2010，64，12： | 1 |
| 11 | Dipeptidyl- peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon- like peptide- 1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum 显示文摘 | MENTLEIN R GALLWITZ B SCHMIDT WE | 1993 | Eur J Biochem1993，214，3： | 1 |
| 12 | 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin:a randomised,double-blind,non-inferiority trial显示文摘 | Gallwitz B Rosenstock J Rauch T | 2012 | Lancet2012，380，： | 1 |
| 13 | Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone : a 52-week randomised controlled trial 显示文摘 | G-ke B Gallwitz B Eriksson J | 2010 | Int J Clin Pract2010，64，12： | 1 |
| 14 | Biological activity of GLP-l-analogues with N-terminal modifications显示文摘 | Siegel EG Gallwitz B Scharf G | 1999 | Regul Pept1999，79，： | 1 |
| 15 | Exenatidc twice daily versus glimepiride for prevention of glyeaemic deterioration in patients with type 2 diabetes with metformin failure (EU- REXA ) : an open-label, randomised controlled trial显示文摘 | GALLWITZ B GUZMAN J DOTTA F | 2012 | Lancet2012，379，9833： | 1 |
| 16 | GLP-l-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro显示文摘 | Gallwitz B Ropeter T Morys-Wortmann C | 2000 | Regul Pept2000，86，13： | 1 |
| 17 | Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus显示文摘 | W. Kothny J. Foley P. Kozlovski Q. Shao B. Gallwitz V. Lukashevich | 2012 | Diabetes Obes Metab2012，，3： | 1 |
| 18 | Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glueagon-like peptide 1 in patients with type 2 diabetes显示文摘 | Meier JJ Gallwitz B Salmen S | 2003 | J Clin Endocrinol Metab2003，88，6： | 1 |
| 19 | Glucagon-like peptide-l-based therapies for the treatment of type 2 diabetes mellitus显示文摘 | Gallwitz B | 2005 | Treat Endocrinol2005，4，6： | 1 |
| 20 | GLP- 1 - analogues resistant to degredation by dipeptidyl - peptidase Ⅳ in vitro 显示文摘 | Gallwitz B Ropeter T Morys - Wortmann | 2000 | Regul Pept2000，86，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员